ANDREW KERSTEIN: Open Payments
NPI 1346473360 · KANSAS CITY, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,636 in 84 payments from 15 companies in 2025. Trend: 2023 $0 · 2024 $665 · 2025 $1,636
Food & beverage: $1,636
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 12 | $319 |
| Teva Pharmaceuticals USA, Inc. | 25 | $315 |
| E.R. Squibb & Sons, L.L.C. | 11 | $308 |
| Otsuka America Pharmaceutical, Inc. | 12 | $191 |
| Alkermes, Inc. | 4 | $107 |
| Almatica Pharma LLC | 5 | $97 |
| Noven Therapeutics, LLC | 3 | $61 |
| Axsome Therapeutics, Inc. | 3 | $56 |
| ABBVIE INC. | 2 | $45 |
| ACADIA Pharmaceuticals Inc | 2 | $41 |
Products named: INGREZZA, AUSTEDO XR, COBENFY, REXULTI, ARISTADA, LOREEV XR, Xelstrym, Auvelity.
Industry payments across MO — which companies pay providers there.
